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High molecular weight (HMW-A) adiponectin levels mirror alterations in glucose homeostasis better than
medium (MMW-A) and low molecular weight (LMW-A) components. In 25 patients with wide-range
extreme obesity (BMI 40-77 kg/m2), we aimed to explore if improvements of multimeric adiponectin
following 4-wkweight loss reflect baselineOGTT-derived insulin sensitivity (ISIOGTT) and disposition index
(DIOGTT). Compared to 40 lean controls, adiponectin oligomers were lower in extreme obesity (p, 0.001)
and, within this group, HMW-A levels were higher in insulin-sensitive (p, 0.05) than -resistant patients. In
obese patients, short-term weight loss did not change total adiponectin levels and insulin resistance, while
the distribution pattern of adiponectin oligomers changed due to significant increment of HMW-A (p ,
0.01) and reduction ofMMW-A (p, 0.05). Bymultivariate analysis, final HMW-A levels were significantly
related to baseline ISIOGTT and final body weight (adjusted R2 5 0.41). Our data suggest that HMW
adiponectin may reflect baseline insulin sensitivity appropriately in the context of extreme obesity.
Especially, we documented that HMW-A is promptly responsive to short-term weight loss prior to changes
in insulin resistance, by amagnitude that is proportioned towhole body insulin sensitivity. Thismay suggest
an insulin sensitivity-dependent control operated by HMW-A on metabolic dynamics of patients with
extreme obesity.
O
besity is associated with a state of chronic low-grade inflammation, insulin resistance and metabolic
disturbances, collectively defined as the metabolic syndrome, which are linked to an increase in cardio-
vascular morbidity and mortality1. Key to the metabolic syndrome is the disproportionate accumulation
of abdominal adipose tissue (AT), the bodies largest endocrine organ, comprised of subcutaneous (SAT) and
visceral AT (VAT). An extensive vascular network supplies adipocytes, thus that even modest alterations in fat
accumulation can impact cellular secretions and physiologically result in variations in metabolism, energy storage,
immunity and inflammation. Of great importance is the role of adipose tissue as a key regulator of lipid and
glucose metabolism via several adipokines such as leptin, adiponectin, TNF-alpha and numerous interleukins2.
Unlike themajority of adipokines, circulating adiponectin is inversely related to bodymass index (BMI) and fat
accumulation, and its ability to control insulin sensitivity has been extensively characterized3,4 in relation to states
of insulin resistance, obesity, type 2 diabetesmellitus (T2DM) and coronary heart disease5–7. Peculiarly, as a result
of the obesity epidemic, there is an increasing number of patients in the extremely obese category (defined as BMI
$ 40 kg/m2). It is shown that the effect of extreme obesity onmortality is greater among young than older adults,
greater among men than women, and greater among whites than blacks8. However, data on the dynamics of
adiponectin is currently limited in this group of patients9.
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Circulating adiponectin is comprised of distinct multimeric moi-
eties including a trimeric lowmolecular weight (LMW), a hexameric
mediummolecular weight (MMW) and an oligomeric high molecu-
lar weight complex (HMW)4. Three different adiponectin receptors
have been identified: the structurally highly related G-protein-
coupled seven-transmembrane-domain receptors AdipoR1 and
AdipoR2, and T-cadherin, a glycosyl-phosphatidyl-inositol-
anchored extracellular protein responsive to HMW and MMW adi-
ponectin4,10. AdipoR1 is expressed in muscle, whereas AdipoR2 is
liver specific and T-cadherin is present in muscle, as well as in
cardiovascular and nervous systems10. Previous investigations in
humans revealed that plasmaHMWadiponectin levels reflect insulin
sensitivity and high density lipoprotein cholesterol levels more
accurately than MMW and LWM oligomers11,12. In obese and non-
obese subjects, profiling of the distribution of multimeric adiponec-
tin by enzyme immunoassay resulted in a better correlation of HMW
adiponectin concentrations to parameters of insulin sensitivity, cir-
culating lipids, VAT, and waist-to-hip ratio than MMW or LMW
adiponectin levels13. It is also acknowledged that there are gender-
related differences in the circulating levels of adiponectin and its
complexes, with women harboring higher levels than men7.
In obese individuals, previous studies on responsiveness of the
composition of multimeric adiponectin following dietary interven-
tion or bariatric surgery have yielded contradictory results, with
some investigations failing to demonstrate significant changes fol-
lowing weight loss14, while others reported increases in HMW,
MMWand LMWconcentrations15,16. Due to differences in the inclu-
sion criteria, sample size and comorbidities across diverse studies,
much uncertainty remains as to the metabolic determinants, or tim-
ing and themagnitude of weight loss, required tomodify adiponectin
moieties in the setting of extreme obesity.
The aim of this study was thus to investigate multimeric adipo-
nectin complexes in patients with extreme obesity (BMI. 40 kg/m2)
previously unknown to be diabetic, in relation to different measures
of insulin sensitivity and in response to short-term weight loss.
Methods
Subjects. Participants were consecutively recruited into the study after signing an
informed consent upon admission to our Institution for routine diagnostic workup
and inpatient rehabilitation for extreme obesity. The study was approved by the local
Ethic Committee. The study population consisted of 25 extreme obese patients (9
females/16 males; mean age, 36.4 6 9.3 yr; mean BMI, 51.5 6 8.4 kg/m2, BMI range,
40–77 kg/m2). As healthy controls, 40 subjects (15 females, age 35.1 6 7.3 yr, BMI
22.4 6 2.1 kg/m2) were recruited among the Institution’s employees and donated
plasma for biochemical analyses. Exclusion criteria were menopause, endocrine
disturbances causing obesity, type 1 diabetes mellitus (T1DM), previous diagnosis of
T2DM, autoimmune or chronic inflammatory disorders, chronic obstructive
pulmonary disease, history of neoplasms or degenerative diseases, previous chronic
steroid treatment, kidney or cardiac disorders. No patient was undergoing
pharmacological therapies at the time of the study, with body weight stable for at least
three months prior to hospital admission. Obese subjects were studied at baseline
upon admission and following a four-week inpatient metabolic rehabilitation
consisting of individualized caloric restriction equivalent to 75% of basal resting
energy expenditure measured by indirect calorimetry17, physical exercise comprising
of three sessions per week of aerobic activity, supported by a nutrition and lifestyle
action program consisting of three 1-hr classes per week dedicated to an educational
approach on dietary behavior, nutrition knowledge and motor activity. Inpatient
hypocaloric diet consisted of 30% lipids, 50% carbohydrates, and 20% proteins.
Neither supplements nor anti-obesity therapies were used during the study period.
The methods were carried out in accordance with the approved guidelines.
Body Measurements. Subjects underwent body measurement wearing light
underwear, in a fasting condition after voiding. Weight and height were measured to
the nearest 0.1 kg and 0.1 cm, respectively. BMI was expressed as weight (kilograms)/
height (meters)2 and obesity was defined for any BMI over 30 kg/m2; all patients
included in this study were affected with extreme obesity (BMI range, 40–77 kg/m2).
Waist circumference was measured midway between the lowest rib and the top of the
iliac crest after gentle expiration; hip measurements were taken as the greatest
circumference around the nates. Anthropometric data were expressed as the mean of
two measurements. All obese subjects underwent dual-energy x-ray absorptiometry
(GE-Lunar, Madison, WI) for measurement of lean and fat body mass, the morning
after an overnight fasting and after voiding.
Metabolic Determinations and Laboratory.Obese patients underwent 2-h 75 g oral
glucose tolerance test (OGTT) for the determination of glucose, insulin and C-
peptide levels. The areas under the curves for glucose (GAUC), insulin (IAUC) and C-
peptide (PAUC) were calculated using the trapezoidal formula. Upon OGTT, ADA
guidelines18 were applied for the assessment of glucose tolerance as follows: normal
fasting plasma glucose (FPG) if ,100 mg/dl (5.6 mmol/l); impaired FPG if 100–
125 mg/dl (6.9 mmol/l); impaired glucose tolerance (IGT) if 2 h OGTT-PG 140–
199 mg/dl (7.8–11.0 mmol/l); T2DM if FPG $ 126 mg/dl ($7 mmol/l) two days
apart or if 2-h OGTT-PG $200 mg/dl ($11.1 mmol/l). Glycated haemoglobin
(HbA1C) values of 5.7 and 6.5% were considered as the threshold for normal glucose
metabolism and T2DM, respectively. Insulin sensitivity was investigated by indices
obtained in fasting conditions or derived from the OGTT, previously validated
against the euglycemic hyperinsulinemic clamp, as follows: FPG; fasting insulin (FI);
fasting C-peptide (FCP); homeostatic model of insulin resistance (HOMA-IR),
calculated as insulin (mU/ml) x [glucose (mmol/l)/22.5]; whole-body insulin
sensitivity index (ISIOGTT), also indicated as the Matsuda index, measured during
OGTT by the composite index19 as [ISIOGTT 5 10,000/square root of (FG 3 FI) 3
(mean glucose 3 mean insulin during OGTT)]; insulinogenic index (IGIOGTT), an
index of first-phase insulin secretion20, calculated as [(insulin at time 30 2 insulin at
time 0)/(glucose at time 30 - glucose at time 0]; disposition index (DIOGTT), a product
of the insulin sensitivity index and the absolute insulin secretion index, calculated as
ISIOGTT x IGIOGTT19.
Blood glucose, electrolytes and HbA1c were measured by enzymatic methods
(Roche Molecular Biochemicals, Mannheim, Germany). A two-site, solid-phase
chemiluminescent immunometric assay or competitive immunoassay was used for
insulin andC-peptide levels (Immulite 2000Analyzer; DPC, Los Angeles, CA). Serum
total adiponectin and adiponectin multimeric forms were determined using the
Adiponectin (Multimeric) enzyme immunoassay (EIA) (ALPCODiagnostics, Salem,
NH), according to the manufacturer’s instructions. Assay sensitivity is 0.019 ng/ml;
as reported by the manufacturer, overall intra- and inter-assay coefficient of varia-
tions (CV) for total, HMW and MMW1LMW are 5.4–7.3% and 5.0–6.0%,
respectively.
Statistical Analysis. Data are expressed as the mean 6 SD. Data were tested for
normality of distribution by the Kolmogorov-Smirnov test. Statistical analyses were
carried out using unpaired and paired two-tailed Student’s t test to compare baseline
characteristics of the two groups and within the obese population at the different
time-points. Linear regression analyses were performed to determine correlation
coefficients between different parameters. Stepwise multivariate regression was used
to evaluate the association between adiponectin oligomers and metabolic or
anthropometric variables after controlling for potential associated variables. b
coefficients and related significance values obtained from the models are reported. P
, 0.05 was considered as statistically significant.
Results
Baseline characteristics of the obese patients are shown in Table 1.
Their mean BMI was 51.6 6 8.4 kg/m2 and the prevalence of IGT
and newly diagnosed T2DM was 52% and 26%, respectively. Two
patients with diabetic FPG levels did not undergo OGTT. Compared
to controls, adiponectin overall was significantly decreased in obese
patients when calculated as total (2.98 6 1.01 vs. 5.62 6 1.28 mg/ml,
p, 0.001) ormeasured as HMW(1.206 0.57 vs. 2.476 0.94 mg/ml,
p , 0.001), MMW (0.70 6 0.26 vs. 1.52 6 0.29 mg/ml, p , 0.001)
and LMW isoforms (1.09 6 0.64 vs. 1.63 6 0.14 mg/ml, p, 0.001).
The HMW-to-total adiponectin ratio was similar between patients
and controls (42.4 6 7.2 vs. 39.5 6 11.9%, NS). Within the obese
group, adiponectin multimers were similar between nondiabetic and
newly diagnosed diabetic patients (Table 2). However, when obese
patients were stratified by ISIOGTT according to a cutoff of 2.5, prev-
iously demonstrated to be a conservative threshold of insulin sens-
Table 1 | Baseline characteristics of the obese study partecipants
Parameters Obese patients (N 5 25)
Age 36.5 6 9.4
Gender (F/M) 9/16
Weight (kg) 145.5 6 25.5
Body mass index (kg/m2) 51.6 6 8.4
Waist (cm) 141.8 6 16.5
Waist-to-hip ratio 0.98 6 0.10
Fat mass (kg) 70.7 6 18.8
Fat mass (%) 49.4 6 7.3
Fat free mass (kg) 72.2 6 16.0
Fat free mass (%) 50.6 6 7.3
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itivity21, the levels of HMW adiponectin were higher in insulin-sens-
itive (ISIOGTT$ 2.5) than insulin-resistant patients (ISIOGTT, 2.5)
(1.42 6 0.47 vs. 0.97 6 0.59, p , 0.05). For the other adiponectin
components, similar values were observed between these obese
subgroups.
After a 4-wk inpatient rehabilitation program, obese patients lost
cumulatively by 7.26 2.7% of their body weight (Table 3). Short-term
weight loss did not alter total adiponectin levels and HOMA-IR
values. However, the distribution pattern of multimeric adiponectin
changed owing to significant increases of HMW adiponectin levels
and the HMW-to-total adioponectin ratio, while MMW adiponectin
significantly decreased. No change in LMW adiponectin levels were
recorded.
In the obese population, simple regression analyses at baseline
failed to provide associations between adiponectin components and
measures of adiposity, such as BMI, waist circumference and percent
fat mass, yet values of HMW-to-total adiponectin ratio were nega-
tively related to waist (r 5 20.51, p , 0.01). Baseline HMW adipo-
nectin levels paralleled values of ISIOGTT (r 5 0.43, p, 0.05; Fig. 1a)
and DIOGTT (r 5 0.42; p, 0.05), while LMW adiponectin levels were
associated to HOMA-IR (r 5 20.43, p, 0.05). Also negative was the
association between total adiponectin and fasting insulin (r 5 20.51,
p, 0.01), PAUC (r 5 20.45, p, 0.05) and GAUC (r 5 243, p, 005).
At the end of the study, HMW adiponectin levels increased pro-
portionately to baseline values of ISIOGTT (r 5 0.53, p, 0.01; Fig. 1)
and final body weight (r 5 20.46, p , 0.05). There was no asso-
ciation between percent change from baseline of HMW adiponectin
and the change in body weight. While total adiponectin was corre-
lated to final values of insulin and HOMA-IR (r 5 20.46 and r 5
20.44, p, 0.05 for both), HMWadiponectin did not appear to do so
(p5 0.08). Baseline and final values of HMW (r5 0.71, p, 0.0001),
MMW (r 5 0.58, p, 0.01) and LMW adiponectin levels (r 5 0.56, p
, 0.01) were tightly correlated (Fig. 2).
By stepwise multivariate regression analysis, final HMW adipo-
nectin levels were predicted by baseline ISIOGTT values (b5 0.50, p5
0.01) and final body weight (b 5 20.41, p 5 0.02). As a whole, this
model explained 41% of the variability of HMW adiponectin levels
after weight loss.
Discussion
Adults with extreme obesity are a small proportion of the population,
but account for a disproportionate amount of medical illnesses and
health care services8. Low-grade inflammation and insulin resistance
explain the increased cardiovascular morbidity in this population.
There is evidence supporting the role of adiponectin as an active link
between obesity and metabolic dysfunction due to its ability to regu-
late glucose homeostasis and insulin sensitivity4. In animal studies,
dysregulated expression of the adiponectin gene and hypoadiponec-
tinaemia caused by overnutrition can promote insulin resistance
prior to development of T2DM3,22. In humans, adiponectin levels
are inversely related to a number of metabolic disorders, i.e. obesity,
visceral adiposity, insulin resistance, liver steatosis, and proathero-
genic lipoproteins5–7. Noticeably, adiponectin circulates as multi-
meric components and the HMW isoform has been shown to
control plasma glucose levels and hepatic insulin sensitivity more
efficiently than MMW and LMW isoforms23. It has been thus pos-
tulated that HMW adiponectin can promote antidiabetic effects by
acting in the liver through intracellular activation of the AMP-acti-
vated protein kinase4.
In this study on extreme obesity, we found all adiponectin iso-
forms to be lower than in controls by a magnitude that was related to
central fat. Especially, we observed that HMW adiponectin levels
were well correlated to the OGTT-derived Matsuda index, which
conventionally reflects the rate of disappearance of plasma glucose
Table 2 | Baseline glucose homeostasis and multimeric adiponectin in the obese population as a whole and after stratification as non-
diabetic and diabetic by OGTT. Significance is shown (unpaired T test) for nondiabetic and newly diagnosed diabetic patients. For
abbreviations: FPG, fasting plasma glucose; FI, fasting insulin; FCP: fasting C-peptide; AUC, area under the OGTT curve; HbA1c, glycated
haemoglobin; HOMA-IR, homeostatic model of insulin resistance; HMW, high molecular weight; MMW, medium molecular weight; LMW,
low molecular weight
Parameters Whole obese population (n 5 25) Nondiabetic patients (n 5 18) Diabetic patients (n 5 7) p
FPG (mg/dl) 99.4 6 30.1 87.8 6 10.1 129.3 6 43.3 0.0007
FI (mU/l) 19.0 6 8.6 16.1 6 6.55 26.5 6 9.26 0.005
FCP (mg/l) 3.80 6 1.55 3.42 6 1.39 5.17 6 1.43 0.02
HbA1c (%) 6.03 6 1.1 5.58 6 0.25 7.17 6 1.69 0.0006
Glucose AUC 17 831.6 6 3 363.1 16 531.8 6 2 497.2 22 251.0 6 1 685.2 0.0001
Insulin AUC 10 324.9 6 4 691.3 9 502.4 6 4 684.1 13 121.4 6 3 890.1 ns
C-peptide AUC 1 210.8 6 317.4 1 144.7 6 294.5 1 435.6 6 316.7 0.07
HOMA-IR 4.77 6 2.75 3.47 6 1.45 8.12 6 2.48 0.0001
Matsuda index (ISIOGTT) 2.66 6 1.29 3.02 6 1.26 1.42 6 0.46 0.02
Disposition index 3.41 6 4.21 4.11 6 4.56 1.05 6 0.85 ns
Insulinogenic index 1.28 6 1.30 1.46 6 1.43 0.70 6 0.38 ns
Total adiponectin (mg/ml) 2.98 6 1.28 3.34 6 0.82 2.52 6 1.06 ns
HMW adiponectin (mg/ml) 1.20 6 0.57 1.43 6 0.38 1.01 6 0.62 ns
MMW adiponectin (mg/ml) 0.70 6 0.26 0.64 6 0.23 0.72 6 0.26 ns
LMW adiponectin (mg/ml) 1.09 6 0.64 1.30 6 0.65 0.78 6 0.73 ns
HMW/total adiponectin (%) 39.5 6 11.9 39.7 6 11.3 39.1 6 13.1 ns
Table 3 | Effect of short -termweight loss on antropometric features,
metabolic parameters, and adiponectin isoforms in the obese
population. For abbreviation: FPG, fasting plasma glucose; FI, fast-
ing insulin; HOMA-IR, homeostatic model of insulin resistance;
HMW, high molecular weight; MMW, medium molecular weight;
LMW, low molecular weight
Variable Baseline After weight loss p
Weight (kg) 145.5 6 25.5 134.9 6 49.5 0.0001
Body mass index (kg/m2) 51.6 6 8.4 48.0 6 7.9 0.0001
FPG (mg/dl) 99.4 6 30.1 94.6 6 9.2 ns
FI (mU/l) 18.9 6 8.6 20.7 6 11.8 ns
Homa-IR 4.77 6 2.75 4.56 6 2.23 ns
Total adiponectin (mg/ml) 2.98 6 1.0 3.09 6 1.02 ns
HMW adiponectin (mg/ml) 1.20 6 0.57 1.54 6 0.66 0.01
MMW adiponectin (mg/ml) 0.70 6 0.26 0.57 6 0.31 0.02
LMW adiponectin (mg/ml) 1.09 6 0.64 1.05 6 0.60 ns
HMW/total adiponectin (%) 39.5 6 11.9 49.8 6 15.0 0.0005
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obtained during the insulin clamp and is thus a reliable measure of
whole body insulin sensitivity19,20,24,25, and were consequently greater
in insulin-sensitive than insulin-resistant patients. Also, HMW adi-
ponectin levels were related to the insulin disposition index, a sur-
rogate marker of insulin secretion in relation to insulin sensitivity
associated to the onset of type 2 diabetes mellitus26. Therefore, cur-
rent data may expand to extreme obesity the link previously shown
between HMW adiponectin and glucose disposal rate in nondiabetic
and diabetic obese subjects11.
Main aim of this study was to investigate non adaptive responses
of adiponectin isoforms to a short-term weight loss program is
extreme obesity. Previous studies on total adiponectin had shown
that stable weight reduction increases adiponectin7, and that .10%
weight loss is required to significantly increase adiponectin levels27.
This event may imply also adaptive mechanisms. In analyses of
adiponectin oligomers, previous studies showed no change14,28,
selective increases of HMW and MMW adiponectin15, or increases
in all multimeric forms after stable weight loss16, with discrepancies
possibly due to different study duration, timing of assessment since
the beginning of diet-therapy, obesity categories under evaluation,
and magnitude of lost weight. Opposed to these findings, the current
study suggest that an even modest weight loss can modify HMW
Figure 1 | Bivariate correlation between the Matsuda Index (ISIOGTT)
and baseline (Panel a) and final (Panel b) HMW adiponectin levels in the
obese population. Coefficients are discussed in the Results section.
Figure 2 | Bivariate correlation between baseline and final levels ofHMW
adiponectin (Panel a), MMW adiponectin (Panel b) and LMW
adiponectin (panel c) in the obese population. Coefficients are discussed
in the Results section.
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adiponectin (142%), HMW-to-total adiponectin ratio (135%) and
MMW adiponectin levels (-18%) in the category of patients with
extreme obesity (40–77 kg/m2). We observed that this event does
not require modifications of insulin resistance and of total adiponec-
tin, does allowing us to hypothesize that HMW adiponectin may
undergo early secretory modifications from adipocytes in response
to even small changes in fat mass. The magnitude of HMW adipo-
nectin increase was greater in insulin-sensitive (58%) than -resistant
patients (28%). Further, multivariate analysis revealed that baseline
insulin sensitivity and final body weight were able to explain cumu-
latively 41% of HMW adiponectin variability caused by weight loss.
While some argued that insulin and insulin sensitivity may act per se
to regulate adiponectin multimerization29,30, our data do not support
this hypothesis. Rather, we speculate that HMW adiponectin
changes are non-adaptive, and possibly dependent on post-trans-
lational modifications of the heavily glycosilated residues of adipo-
nectin31, which are influenced by self-regulatory mechanisms34 and
modifications of proinflammatory adipocytokines35 consequent to
changes in fat accumulation32,33.
The limited study sample and the lack of long term data are main
study limitations, and thus neglect the role of long-termweight man-
agement on changes of insulin sensitivity via multimeric adiponectin
actions. We are inclined to consider as potential points of strength
both in the inclusion of patients with very high BMI ranges and the
controlled inpatient weight management schedule, which allowed to
detect short-term non-adaptive responses of multimeric adiponectin
to weight loss.
Based on our findings, we suggest that HMW adiponectin may
appropriately reflect insulin sensitivity and secretion in the context of
extreme obesity, and that an even modest short-term weight loss
influences the distribution pattern of adiponectin oligomers by priv-
ileging selective increments in HMW adiponectin, in proportion to
inherent insulin sensitivity but prior to anymetabolic improvements.
Our data may, thus, suggest that HMW adiponectin acts as an early
regulator of metabolic homeostasis in extreme obesity. Further stud-
ies should investigate long-term interaction between adiponectin
components and insulin resistance in this setting.
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